Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of SOL-116 in healthy volunteers and patients with rheumatoid arthritis
NL-OMON56208Phase 1Completed
- Sponsor
- Lipum AB
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing SOL-116 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Oct 2022; status: completed.
02
Drugs
SOL-116
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON56208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56208.